Model for end-stage liver disease (MELD) exception for hereditary hemorrhagic telangiectasia by Garcia-Tsao, Guadalupe et al.
MELD SUPPLEMENT
Model for End-Stage Liver Disease (MELD)
Exception for Hereditary Hemorrhagic
Telangiectasia
Guadalupe Garcia-Tsao,1 Robert G. Gish,2 and Jeffrey Punch3
From 1Yale University School of Medicine, New Haven, CT; 2Departments of Medicine and Transplantation
and the Division of Hepatology and Complex Gastroenterology, Physicians Foundation, California Pacific
Medical Center, San Francisco, CA; and 3University of Michigan, Ann Arbor, MI
Hereditary hemorrhagic telangiectasia (HHT), also
called Rendu-Osler-Weber syndrome, is a rare autoso-
mal dominant disease characterized by arteriovenous
malformations involving the skin, mucous membranes,
lungs, brain, and gastrointestinal tract. The genetic or-
igin of this disease appears to be a defect in transmem-
brane proteins that are components of the receptor
complex for transforming growth factor- (endoglin, ac-
tivin receptor like-kinase 1). Hepatic involvement is fre-
quent, but it is asymptomatic in most cases. HHT is
characterized by diffuse vascular malformations
throughout the liver that result in multiple types of
shunting (hepatic artery to hepatic vein, hepatic artery
to portal vein, portal vein to hepatic vein), with hepatic-
artery-to-hepatic-vein shunting being the predominant
type.
Symptomatic liver involvement can present as (1)
high output cardiac failure (most common presenta-
tion), (2) portal hypertension (from hepatic-artery-to-
portal-vein shunting and/or nodular regenerative hy-
perplasia), and/or (3) biliary abnormalities such as
stricturing and necrosis (probably from ischemia).1 A
patient may have overlapping presentations, and over
time, the predominant presentation may transition
from one type to another.2 Although the diagnosis is not
made histologically, the principal features of hepatic
HHT are periportal telangiectases with accompanying
fibrous tissue and sinusoidal congestion and dilata-
tion.3 Liver transplantation (LT) may be indicated in
cases of intractable heart failure, biliary sepsis, and
intrahepatic hemorrhage. Hereditary hemorrhagic tel-
angiectasia does not appear to progress to cirrhosis,
and even though patients may have portal hypertension
(with varices and ascites), they generally do not develop
liver insufficiency. Diagnosis is made radiographically,
most often with an abdominal computed tomography
scan demonstrating diffuse heterogenous enhance-
ment of the liver and an enlarged hepatic artery. Histo-
logic examination is unnecessary and may be danger-
ous.
Liver transplantation for HHT is a difficult procedure.
Embolization or operative hepatic artery ligation has
been attempted for high-output heart failure; however,
experience with these procedures is limited, and results
are inconsistent and not durable.4,5 More importantly,
biliary and liver necrosis leading to acute liver failure
have been reported following hepatic artery emboliza-
tion; therefore, this procedure is not recommended.5
Heart failure can be triggered during pregnancy, and
spontaneous regression of symptoms after delivery has
been reported.6
Most published accounts of LT for HHT are single-
case reports. The largest series in the literature, from
France, describes 6 patients.1 From this experience, in
which the median blood loss was 59 units, LT appears
to be a difficult procedure due to the hypervascular
nature of the liver. Other cases of unsuccessful LT due
to fatal intraoperative hemorrhage have been de-
scribed. The survival rate in this series was 66%, but at
least 16 additional patients have been described who
received LT for HHT, and all but 1 survived. Hemody-
namic studies have indicated that the hyperdynamic
state resolves in all cases. Therefore, LT is a reasonably
successful option in this setting.
The natural history of hepatic involvement of HHT is
unclear. The largest experience, described by Garcia-
Tsao and colleagues, included 19 patients with hepatic
HHT.1 Eight of the 19 patients had symptomatic high-
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output cardiac failure. The condition of 3 patients im-
proved, 4 were in stable condition with medical therapy,
and 1 died after a median follow-up period of 24
months. Six patients had manifestations of portal hy-
pertension, such as ascites or variceal bleeding. After a
median follow-up period of 19 months, the condition of
2 of the 6 patients improved, and the remaining 4 pa-
tients died. Five patients had manifestations of biliary
disease. After a median follow-up period of 30 months,
the condition of 2 of the 5 patients improved, the con-
dition of 1 was unchanged, heart failure developed in 1,
and 1 died after an unsuccessful attempt at LT. From
this experience, it appears that progressive disease
leading to mortality is frequent but not universal. More
recent data show that patients with heart failure who
develop biliary ischemia have the highest mortality
rate.
SYNTHESIS OF AVAILABLE DATA
There is insufficient objective evidence to justify auto-
matic additional priority for patients with HHT.
PROPOSAL FOR STANDARDIZED MODEL FOR
END-STAGE LIVER DISEASE (MELD)
EXCEPTIONS FOR CANDIDATES WITH HHT
At this time, we propose that patients with HHT con-
tinue to be addressed by the regional review boards and
additional priority be assigned on a case-by-case basis.
Additional priority should not be automatically granted
at this time. Our suggestions for the regional boards are
to assign a MELD score of 40 to patients with acute
biliary necrosis and a MELD score of 22 to patients with
intractable heart failure.
INCREMENTAL INCREASES IN MELD SCORE
If an increased MELD score is provided, the MELD score
should increase by an incremental 10% mortality risk
score at 3-month intervals on a case-by-case basis after
the regional review board has evaluated all of the infor-
mation defined above for each 3-month cycle.
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